Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/4/2025 | $16.00 | Neutral → Buy | BTIG Research |
| 12/31/2024 | $14.50 | Buy | Lake Street |
| 12/17/2024 | $8.00 | Neutral | Analyst |
| 5/16/2024 | $16.00 → $6.50 | Buy → Neutral | UBS |
| 5/8/2024 | $15.00 → $5.50 | Overweight → Equal-Weight | Morgan Stanley |
| 5/8/2024 | $17.00 → $7.00 | Buy → Hold | Truist |
| 5/8/2024 | $15.00 → $6.00 | Buy → Hold | Stifel |
| 5/8/2024 | $15.00 → $8.00 | Overweight → Neutral | JP Morgan |
PONTE VEDRA, Fla., March 25, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced new technology innovations featured at the 2025 American College of Foot and Ankle Surgeons ("ACFAS") Annual Scientific Conference in Phoenix, Arizona from March 27-30, 2025. "We are excited to have another strong presence at ACFAS, highlighting our commitment to surgical podiatry and advancing our company's focused mission to improve surgical outcomes for bunio
PONTE VEDRA, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Revenue of $68.7 million in fourth quarter 2024 increased 10% over same period in 2023. Revenue of $209.4 million for full-year 2024 increased 12% compared to the prior year.Fourth quarter 2024 net loss was ($0.5) million compared to ($6.3) million for same period in
PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Thursday, February 27, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will rec
BTIG Research upgraded Treace Medical Concepts from Neutral to Buy and set a new price target of $16.00
Lake Street initiated coverage of Treace Medical Concepts with a rating of Buy and set a new price target of $14.50
Analyst resumed coverage of Treace Medical Concepts with a rating of Neutral and set a new price target of $8.00
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
10-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
SCHEDULE 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace's commercial efforts and play a pivotal role in driving the Company's next phase of rapid innovation, strategic product commercialization, and growth. "I am thrilled to welcome Guy to the Treace team," said John T. Treace, CEO, Founder and B
PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace's marketing efforts, with a focus on expanding the Company's physician outreach, patient awareness and market penetration efforts. "I am delighted to welcome Nathan to the Treace team," said John T. Treace, CEO, Fou
PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer, effective July 17, 2023. In this new position, Ms. Dewey will lead all aspects of Treace's corporate communications and investor relations engagement, with a focus on expanding the company's outreach with the investment community and broadening the Company's relationships wit
PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Thursday, February 27, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will rec
PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results. Highlights: Preliminary revenue of $68.4 million to $68.8 million in the fourth quarter of 2024, an approximate 10% increase at the midpoint over the same period in 2023.Preliminary revenue of $209.0 million to $209.4 million for the full-year 2024, an approximate 12% increase at the midpoint
PONTE VEDRA, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Tuesday, November 5, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in nu
SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)